NCT06590012View on ClinicalTrials.gov

Evaluating the Impact of 'Tertinat' on Patients with Atherosclerosis-Related Cardiovascular Diseases

PHASE2RecruitingINTERVENTIONAL
Enrollment

556

Participants

Timeline

Start Date

August 29, 2024

Primary Completion Date

August 29, 2025

Study Completion Date

March 1, 2026

Conditions
AtherosclerosisAtheroscleroses, CoronaryCarotid Atherosclerosis
Interventions
DRUG

Placebo

Participants will take the placebo capsules in addition to standard treatment for a year.

DRUG

Tertinat

Participants will take Tertinat capsules in addition to standard treatment for a year.

Trial Locations (1)

121609

RECRUITING

Institute for Atherosclerosis Research, Moscow

All Listed Sponsors
lead

Institute for Atherosclerosis Research, Russia

OTHER